109
Participants
Start Date
September 14, 2023
Primary Completion Date
October 24, 2024
Study Completion Date
October 30, 2024
DA-1241
Route of Administration: Oral, with subjects in a fasting state
Sitagliptin
Route of Administration: Oral, with subjects in a fasting state
DA-1241 Placebo
Route of Administration: Oral, with subjects in a fasting state
Sitagliptin Placebo
Route of Administration: Oral, with subjects in a fasting state
Clinical Pharmacology of Miami, LLC, Miami
Floridian Clinical Research, Miami Lakes
Integrity Clinical Research, LLC, Doral
Suncoast Research Group, LLC, Miami
GI Associates & Endoscopy Center, Flowood
Dallas Research Institute, LLC, Farmers Branch
Pioneer Research Solutions Inc., Houston
American Research Corporation, San Antonio
Pinnacle Clinical Research - San Antonio, San Antonio
Apex Mobile Clinical Research, LLC, San Antonio
South Texas Research Institute - A Pinnacle Entity, Edinburg
Pinnacle Clinical Research - Georgetown, Georgetown
Velocity Clinical Research, Panorama City, Panorama City
Catalina Research Institute, LLC, Montclair
Southern California Research Center, Coronado
Inland Empire Clinical Trials, LLC, Rialto
Liver Institute Northwest, Seattle
AIG Digestive Disease Research, Florham Park
Lead Sponsor
NeuroBo Pharmaceuticals Inc.
INDUSTRY